Reaching a peak in the 80s, the infamous AIDS epidemic was a deadly global health crisis shrouded in misinformation and stigma. With the heroic advent of effective antiretroviral therapy (ART) a decade later, this fatal condition fell to a chronic, manageable disease. Yet, in the same era which has given us personalised cancer vaccines, we are yet to find a true cure to this viral infection. With the immediate danger of infection averted, has the search for a cure fallen by the wayside?
Cellular latency is a huge barrier in our efforts to rid the body of the HIV virus in its entirety. Host CD4+ T cells effectively become a welcome shelter for this virus and in doing so, hide it from both the immune system and any pharmacological intervention we choose to throw at it. Some of the most exciting and cutting-edge research therefore aims to bring the virus out of its adoptive shelter. Latency-reversing agents (LRAs) have, in fact, existed for decades, but with little success. As with many other drugs, it is delivery, not action, that is the issue. Prompted by the COVID-19 pandemic, huge leaps in mRNA and lipid particle technology are revolutionising the field.
Delivering viral mRNA into cells of the immune system has only recently become more than an immunologist’s fantasy. COVID-19 taught us many lessons about how to deliver this biochemical ‘heads up’ in a stable and immunogenic manner – and in doing so likely saved millions of lives globally. Using the momentum from this success, Cevaal et al (2025) developed a new mRNA delivery system known as ‘LNP X’. Their published results highlight effective delivery of encapsulated viral mRNA to the immune system, which is then able to mount a response to these latent reservoirs.
When it comes to what the mRNA is encoding, we need to strike the heart of the beast, in this case, delivered via code for a viral replication ‘master switch’ known as Tat. Showing great promise, Cevaal’s approach was able to transfect cells at a much greater rate than its Nobel-prize-winning competitor: a CRISPR-cas-9 based activation system. This CRISPR system identifies and cleaves key transcription sites required for viral survival, yet falls short compared to the novel advanced mRNA delivery system.
Despite this superficial success, it is naïve to think that latency reversal alone is sufficient for clinical translation. While much more potent than traditional delivery systems, LPN X has failed to demonstrate actual depletion of HIV reservoirs in host CD4+ T cells. Moreover, the ever-present challenges of patient safety, dosing, and off-target effects all remain ahead of us.
Despite these teething issues, the work of Cevaal et al. has created a breakthrough platform for science to build upon, meaning, almost half a century on from the height of the AIDs epidemic, the future appears bright for a true HIV cure.
Reaching a peak in the 80s, the infamous AIDS epidemic was a deadly global health crisis shrouded in misinformation and stigma. With the heroic advent of effective antiretroviral therapy (ART) a decade later, this fatal condition fell to a chronic, manageable disease. Yet, in the same era which has given us personalised cancer vaccines, we are yet to find a true cure to this viral infection. With the immediate danger of infection averted, has the search for a cure fallen by the wayside?
Cellular latency is a huge barrier in our efforts to rid the body of the HIV virus in its entirety. Host CD4+ T cells effectively become a welcome shelter for this virus and in doing so, hide it from both the immune system and any pharmacological intervention we choose to throw at it. Some of the most exciting and cutting-edge research therefore aims to bring the virus out of its adoptive shelter. Latency-reversing agents (LRAs) have, in fact, existed for decades, but with little success. As with many other drugs, it is delivery, not action, that is the issue. Prompted by the COVID-19 pandemic, huge leaps in mRNA and lipid particle technology are revolutionising the field.
Delivering viral mRNA into cells of the immune system has only recently become more than an immunologist’s fantasy. COVID-19 taught us many lessons about how to deliver this biochemical ‘heads up’ in a stable and immunogenic manner – and in doing so likely saved millions of lives globally. Using the momentum from this success, Cevaal et al (2025) developed a new mRNA delivery system known as ‘LNP X’. Their published results highlight effective delivery of encapsulated viral mRNA to the immune system, which is then able to mount a response to these latent reservoirs.
When it comes to what the mRNA is encoding, we need to strike the heart of the beast, in this case, delivered via code for a viral replication ‘master switch’ known as Tat. Showing great promise, Cevaal’s approach was able to transfect cells at a much greater rate than its Nobel-prize-winning competitor: a CRISPR-cas-9 based activation system. This CRISPR system identifies and cleaves key transcription sites required for viral survival, yet falls short compared to the novel advanced mRNA delivery system.
Despite this superficial success, it is naïve to think that latency reversal alone is sufficient for clinical translation. While much more potent than traditional delivery systems, LPN X has failed to demonstrate actual depletion of HIV reservoirs in host CD4+ T cells. Moreover, the ever-present challenges of patient safety, dosing, and off-target effects all remain ahead of us.
Despite these teething issues, the work of Cevaal et al. has created a breakthrough platform for science to build upon, meaning, almost half a century on from the height of the AIDs epidemic, the future appears bright for a true HIV cure.
